Compare Paycom Software Inc (PAYC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs TG Therapeutics Inc — how do they compare? Paycom Software Inc trades at $214.7 (market cap $9.88B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Paycom Software Inc is the larger of the two by market cap, and Paycom Software Inc pays a 0.68% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PAYC | TGTX | |
|---|---|---|
Market Cap | $9.88B | $8.53B |
Sector | Technology | Health |
52-Week High | $240.52 | $59.06 |
52-Week Low | $113.59 | $26.94 |
Enterprise Value | $10.66B | $8.74B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $219.16, down 5.4% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal despite recent weakness, supported by positive analyst sentiment and institutional accumulation. Recent Q2 2026 results exceeded expectations with EPS of $2.78 beating estimates of $2.38, driving management's raised full-year guidance.
Outlook remains positive with a consensus price target of $231.70 offering 5.7% upside potential. Key opportunities include sustained revenue growth and expanding margins, while risks involve competitive pressures and market volatility. The company's strong cash flow generation and shareholder returns through dividends and buybacks support long-term value creation.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
